Nothing Special   »   [go: up one dir, main page]

AU756828B2 - Transdermal delivery of particulate vaccine compositions - Google Patents

Transdermal delivery of particulate vaccine compositions Download PDF

Info

Publication number
AU756828B2
AU756828B2 AU16199/99A AU1619999A AU756828B2 AU 756828 B2 AU756828 B2 AU 756828B2 AU 16199/99 A AU16199/99 A AU 16199/99A AU 1619999 A AU1619999 A AU 1619999A AU 756828 B2 AU756828 B2 AU 756828B2
Authority
AU
Australia
Prior art keywords
adjuvant
dose
antigen
composition
particulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU16199/99A
Other languages
English (en)
Other versions
AU1619999A (en
Inventor
Dexiang Chen
Robert J. Drape
David Sarphie
William F. Swain
Georg J. Widera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Powderject Vaccines Inc
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Publication of AU1619999A publication Critical patent/AU1619999A/en
Application granted granted Critical
Publication of AU756828B2 publication Critical patent/AU756828B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU16199/99A 1997-12-02 1998-12-02 Transdermal delivery of particulate vaccine compositions Ceased AU756828B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6714697P 1997-12-02 1997-12-02
US60/067146 1997-12-02
US8268698P 1998-04-22 1998-04-22
US60/082686 1998-04-22
PCT/US1998/025563 WO1999027961A1 (fr) 1997-12-02 1998-12-02 Administration transdermique de compositions particulaires de vaccins

Publications (2)

Publication Number Publication Date
AU1619999A AU1619999A (en) 1999-06-16
AU756828B2 true AU756828B2 (en) 2003-01-23

Family

ID=26747529

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16199/99A Ceased AU756828B2 (en) 1997-12-02 1998-12-02 Transdermal delivery of particulate vaccine compositions

Country Status (9)

Country Link
EP (1) EP1035867A1 (fr)
JP (1) JP2001524533A (fr)
CN (1) CN1285753A (fr)
AU (1) AU756828B2 (fr)
CA (1) CA2312900A1 (fr)
HU (1) HUP0101139A3 (fr)
IL (1) IL136488A0 (fr)
NZ (1) NZ504894A (fr)
WO (1) WO1999027961A1 (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7223739B1 (en) 1995-06-07 2007-05-29 Powderject Vaccines, Inc. Adjuvanted genetic vaccines
US7022320B1 (en) 1999-02-09 2006-04-04 Powderject Vaccines, Inc. Mycobacterium tuberculosis immunization
CA2376992A1 (fr) * 1999-06-29 2001-01-04 Smithkline Beecham Biologicals S.A. Vaccin
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
WO2001026717A1 (fr) 1999-10-11 2001-04-19 Needleless Ventures, Inc. Protecteur universel contre les infections pour injecteurs sans aiguille
SI1227840T1 (sl) * 1999-11-03 2008-02-29 Powderject Vaccines Inc Genetske vakcine z adjuvansom
JP2003516936A (ja) * 1999-11-03 2003-05-20 パウダージェクト ヴァクシンズ，インコーポレイテッド アジュバント化遺伝子ワクチン
IL149458A0 (en) * 1999-11-10 2002-11-10 Powderject Vaccines Inc Induction of mucosal immunity by vaccination via the skin route
US7887506B1 (en) 1999-11-23 2011-02-15 Pulse Needlefree Systems, Inc. Safety mechanism to prevent accidental patient injection and methods of same
CA2412197A1 (fr) * 2000-06-08 2001-12-13 Powderject Vaccines, Inc. Compositions de poudre
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
DK2266603T3 (da) 2000-10-18 2012-11-05 Glaxosmithkline Biolog Sa Tumorvacciner
US8466116B2 (en) * 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
JP4842128B2 (ja) 2003-07-21 2011-12-21 トランジェーヌ、ソシエテ、アノニム 新規多機能性サイトカイン
EP2612679A1 (fr) 2004-07-29 2013-07-10 Novartis Vaccines and Diagnostics, Inc. Compositions immunogènes pour une bactérie à gram positif telle que streptococcus agalactiae
CA2580103C (fr) 2004-09-22 2021-11-16 Glaxosmithkline Biologicals S.A. Composition immunogene
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
PT1951299E (pt) 2005-11-04 2012-02-28 Novartis Vaccines & Diagnostic Vacinas contra a gripe que incluem combinações de adjuvantes particulados e imuno-potenciadores
CA2628397C (fr) * 2005-11-04 2013-08-20 Novartis Vaccines And Diagnostics S.R.L. Modification de l'equilibre th1/th2 dans des vaccins antigrippaux sous-unitaires avec adjuvants
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
LT2384765T (lt) 2005-12-22 2017-01-10 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae vakcina
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
ATE522541T1 (de) 2006-06-09 2011-09-15 Novartis Ag Bakterielle adhäsine konformere
PL2086582T3 (pl) 2006-10-12 2013-04-30 Glaxosmithkline Biologicals Sa Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie
WO2008043774A1 (fr) 2006-10-12 2008-04-17 Glaxosmithkline Biologicals S.A. Vaccin
WO2008137747A1 (fr) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Compositions thérapeutiques à base de nanoémulsion et leurs procédés d'utilisation
EA020817B1 (ru) 2007-06-26 2015-02-27 Глаксосмитклайн Байолоджикалс С.А. Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
MX2010002773A (es) 2007-09-12 2010-03-31 Novartis Ag Antigenos mutantes de gas57 y anticuerpos de gas57.
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
RU2498994C2 (ru) 2007-12-21 2013-11-20 Новартис Аг Мутантные формы стрептолизина о
ES2553113T3 (es) 2008-04-16 2015-12-04 Glaxosmithkline Biologicals S.A. Vacuna
JP5722782B2 (ja) 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
EP2376089B1 (fr) 2008-11-17 2018-03-14 The Regents of the University of Michigan Compositions de vaccins contre le cancer et leurs méthodes d' utilisation
US8465751B2 (en) 2009-01-12 2013-06-18 Novartis Ag Cna—B domain antigens in vaccines against gram positive bacteria
EA023662B1 (ru) 2009-02-10 2016-06-30 Новартис Аг Вакцины против гриппа со сниженным количеством сквалена
RU2011140508A (ru) 2009-03-06 2013-04-20 Новартис Аг Антигены хламидии
EP2944320A1 (fr) 2009-06-15 2015-11-18 National University of Singapore Vaccin contre la grippe, composition et procédés d'utilisation
US20100316673A1 (en) 2009-06-16 2010-12-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JP5633152B2 (ja) * 2010-02-16 2014-12-03 東ソー株式会社 アジュバント
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
WO2011127316A1 (fr) 2010-04-07 2011-10-13 Novartis Ag Procédé de génération de pseudo-particules virales de parvovirus b19
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
CN103154242B (zh) 2010-07-06 2015-09-30 诺华股份有限公司 诺如病毒衍生的免疫原性组合物和方法
GB2482691B (en) * 2010-08-10 2013-08-14 Nemaura Pharma Ltd Structures for transdermal drug delivery
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
BR112013029514A2 (pt) 2011-05-17 2019-09-24 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, método de tratar ou impedir uma doença
US20130189303A1 (en) 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
US9511130B2 (en) 2011-09-14 2016-12-06 Glaxosmithkline Biologicals Sa Escherichia coli vaccine combination
EP2870238A4 (fr) 2012-07-05 2016-03-09 Ohio State Innovation Foundation Compositions et procédés associés à des vaccins viraux
EP2912069B1 (fr) 2012-10-23 2019-07-31 Emory University Conjugués de gm-csf et d'il-4, compositions et procédés associés
JP2016501515A (ja) 2012-10-24 2016-01-21 プレートレット ターゲテッド セラピューティクス，エルエルシー 血小板標的化治療
CA2928700C (fr) 2013-11-01 2019-01-15 University Of Oslo Variants d'albumine et utilisations de ceux-ci
EP3068426B1 (fr) 2013-11-13 2020-02-12 University Of Oslo Vésicules de membrane externe et utilisation associées
US11452767B2 (en) 2013-11-15 2022-09-27 Oslo Universitetssykehus Hf CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
AU2014359292B2 (en) 2013-12-03 2019-02-28 Swiss Tropical And Public Health Institute Proline-rich peptides protective against S. pneumoniae
US11083788B2 (en) 2014-10-10 2021-08-10 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
MA40920A (fr) 2014-11-07 2017-09-12 Takeda Vaccines Inc Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
AR102548A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
EP4226937A3 (fr) 2015-03-05 2023-09-27 Northwestern University Virus non neuro-invasifs et leurs utilisations
CA2996762A1 (fr) 2015-08-31 2017-03-09 Technovax, Inc. Vaccin a base de pseudoparticules virales (vlp) contre le virus syncytial respiratoire humain (hrsv)
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
US12076397B2 (en) 2016-05-10 2024-09-03 The Regents Of The University Of Michigan Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
US11173207B2 (en) 2016-05-19 2021-11-16 The Regents Of The University Of Michigan Adjuvant compositions
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
WO2018096396A1 (fr) 2016-11-22 2018-05-31 University Of Oslo Variants d'albumine et leurs utilisations
JP7182568B2 (ja) 2017-05-22 2022-12-02 トパドゥール ファーマ アーゲー 新規二重作用モード可溶性グアニル酸シクラーゼ活性化因子およびホスホジエステラーゼ阻害剤ならびにその使用
AU2018290298B2 (en) 2017-06-23 2024-03-28 Affinivax, Inc. Immunogenic compositions
EP3678698A1 (fr) 2017-09-07 2020-07-15 University Of Oslo Molécules de vaccin
EP3678699A1 (fr) 2017-09-07 2020-07-15 University Of Oslo Molécules vaccinales
CN111511395B (zh) 2017-11-03 2024-10-15 武田疫苗股份有限公司 用于将寨卡病毒灭活和用于确定灭活完全性的方法
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
EP3887376A1 (fr) 2018-11-28 2021-10-06 Topadur Pharma AG Nouveaux activateurs de la guanylate cyclase solubles à double mode d'action, inhibiteurs de phosphodiestérase et leurs utilisations
WO2021245192A1 (fr) 2020-06-04 2021-12-09 Topadur Pharma Ag Nouveaux activateurs de la guanylate cyclase soluble à double mode d'action et inhibiteurs de phosphodiestérase et leurs utilisations
WO2023039108A1 (fr) 2021-09-08 2023-03-16 Affinivax, Inc. Vaccin anti-coronavirus
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US509188A (en) * 1893-11-21 Barton b
WO1994009819A1 (fr) * 1992-11-03 1994-05-11 Secretech, Inc. Cellulose microcristalline en tant qu'adjuvant immun
WO1997040163A1 (fr) * 1996-04-19 1997-10-30 Metin Colpan Vaccination avec des acides nucleiques contre les infections parvovirales

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4629782A (en) * 1984-12-21 1986-12-16 Syntex (U.S.A.) Inc. Crystalline form of N-acetylmuramyl-L-α-aminobutyryl-D-isoglutamine
CA1337047C (fr) * 1988-08-18 1995-09-19 Peter Dodd Cooper Compositions a base de gamma inuline
DE69005679T2 (de) * 1989-03-29 1994-06-23 Takeda Chemical Industries Ltd Zusammensetzung mit einer Verbindung der Vitamin B-Gruppe und ihre Herstellung.
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US509188A (en) * 1893-11-21 Barton b
WO1994009819A1 (fr) * 1992-11-03 1994-05-11 Secretech, Inc. Cellulose microcristalline en tant qu'adjuvant immun
WO1997040163A1 (fr) * 1996-04-19 1997-10-30 Metin Colpan Vaccination avec des acides nucleiques contre les infections parvovirales

Also Published As

Publication number Publication date
AU1619999A (en) 1999-06-16
WO1999027961A1 (fr) 1999-06-10
IL136488A0 (en) 2001-06-14
CA2312900A1 (fr) 1999-06-10
NZ504894A (en) 2002-12-20
HUP0101139A3 (en) 2003-11-28
JP2001524533A (ja) 2001-12-04
HUP0101139A2 (hu) 2001-07-30
EP1035867A1 (fr) 2000-09-20
CN1285753A (zh) 2001-02-28

Similar Documents

Publication Publication Date Title
AU756828B2 (en) Transdermal delivery of particulate vaccine compositions
EP0991403B1 (fr) Utilisation de microparticules contenant un antigene adsorbe dans le but de stimuler les reponses immunitaires
ES2337017T3 (es) Procedimiento para obtener respuestas inmunitarias celulares de proteinas.
US20050266021A1 (en) Powder compositions
HU228144B1 (en) The use of active ingredient for producing medicament, for transdermal delivery using needleless syringe
Chen et al. Adjuvantation of epidermal powder immunization
KR20030020294A (ko) 분말 조성물
US20060228375A1 (en) Induction of mucosal immunity by vaccination via the skin route
Chen et al. Nanotechnologies applied in biomedical vaccines
Perrie et al. Recent developments in particulate-based vaccines
Glück et al. Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems
AU784781B2 (en) Induction of mucosal immunity by vaccination via the skin route
Sahni et al. Vaccine Delivery: current Routes of Administration and Novel Approaches
MXPA00005348A (es) Administracion transdermica de composiciones particuladas para vacunas
US20040213798A1 (en) Spray-dried alum compositions
Seid Jr et al. Advances in transcutaneous vaccine delivery
CA2389686A1 (fr) Vaccins genetiques assortis d'un adjuvant
EP2683388A2 (fr) Formulation vaccinale de particules peptidiques enrobées de mannose
Tomar Paving the way for pulmonary influenza vaccines: Exploring formulations, models and site of deposition
Seid Jr et al. Transcutaneous immunization via vaccine patch delivery system
Amorij et al. Development of stable influenza vaccine powder formulations for non-parenteral dosage forms: challenges and possibilities.
EP1275380A1 (fr) Utilisation de microparticules contenant un antigene adsorbe dans le but de stimuler les reponses immunitaires
AU2001275371A1 (en) Powder compositions

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)